NATICK, Mass. – June 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced the appointment of Vincent Ricci as Chief Financial Officer. Mr. Ricci will lead Pillar Bioscience’s finance and investor relations functions as the company executes on its growth strategy.
“I am delighted to welcome Vincent to the Pillar team. With his extensive experience as an investment professional in the global healthcare sector, Vincent’s deep insights into the industry will help drive critical growth initiatives for the company,” said Randy Pritchard, CEO of Pillar Biosciences. “I look forward to his contributions as we continue to scale the organization and expand our innovative pipeline of NGS testing solutions.”
“Pillar has a critical mission to transform the cancer testing and treatment landscape by increasing the accessibility of NGS tests and reducing time from diagnosis to therapy selection. The ability to make a meaningful, positive impact on cancer patients’ lives by localizing NGS testing to provide clinicians accurate and actionable results in a timely manner is of undeniable interest to me. I am excited to be part of the future of a company that’s doing such beneficial work for the oncology community,” said Vincent Ricci, CFO of Pillar Biosciences.
Mr. Ricci has two decades of experience as an investment professional focusing on the global healthcare and life sciences industry. He joins Pillar Biosciences from Davidson Kempner Capital Management LP, where he was responsible for equity investments in the life sciences sector. Previously, Mr. Ricci was a Portfolio Manager for Alliance Bernstein where he managed investments across the global healthcare industry. Mr. Ricci began his career at Wachovia Bank N.A. in their Capital Markets division where he was a Vice President and Senior Equity Analyst covering the small and mid-cap medical device industry. Mr. Ricci received his Master of Medical Science from Drexel University College of Medicine and his Bachelor of Arts in Economics and Biology from the University of Pennsylvania.
About Pillar Biosciences
Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar’s NGS testing solutions, including the FDA-approved oncoReveal™ Dx Lung and Colon Cancer Assay, are powered by the Company’s proprietary SLIMamp® and PiVAT® technologies, and decentralizes the testing process, reducing diagnostic costs and improving access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The Company has more than 20 NGS testing products available in IVD or RUO formats, and several others in various stages of development, including a pan-cancer oncoReveal™ CDx assay, and two liquid biopsy offerings. Pillar’s patented technologies have been shown to provide accurate and actionable data in as little as 48 hours, which allows physicians to select appropriate therapies and monitor the patient’s response. Pillar Biosciences has operations in Natick, MA and Shanghai, China. For more information, visit www.pillarbiosci.com.
Joshua R. Mansbach